Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Kinross Gold Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.5 (market cap $5.07B), while Kinross Gold Corporation trades at $27.54 (market cap $32.29B). The key difference: Kinross Gold Corporation is far larger — about 6.4× ACADIA Pharmaceuticals Inc.'s market cap, and Kinross Gold Corporation pays a 0.59% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | KGC | |
|---|---|---|
Market Cap | $5.07B | $32.29B |
Sector | Health | Basic Materials |
52-Week High | $29.41 | $38.06 |
52-Week Low | $20.06 | $18.70 |
Enterprise Value | $4.19B | $30.37B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
Kinross Gold (KGC) trades at $27.59, up 0.69% with strong fundamental momentum. The company demonstrates robust earnings growth with three consecutive quarterly beats and impressive profitability metrics including 37.52% net margin and 36.95% ROE. Recent S&P upgrade to 'BBB' and positive project developments at Lobo-Marte support the bullish analyst consensus.
Outlook remains positive with 29 analysts showing 58.6% buy ratings and $37.20 consensus target, representing 35% upside. Key risks include gold price volatility and execution challenges at new projects. Strong free cash flow generation and disciplined capital allocation support continued shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
